Skip to content

Vertebral column lesion in multiple myeloma- a prospective observation study

Vertebral column lesion in multiple myeloma- a prospective observation study - M2Spine Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00033326
Enrollment
150
Registered
2024-03-04
Start date
2023-01-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90.0

Interventions

Group 1: Conservative management Group 2: Surgical management

Sponsors

Universitätsmedizin Charitè Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Multiple Myeloma patients with vertebral column lesions

Exclusion criteria

Exclusion criteria: Spinal metastases due to other tumor entities Plasmocytoma Age <18 years Patient unable to consent

Design outcomes

Primary

MeasureTime frame
The primary endpoint encompasses the development of Patient Reported Outcome Measures (PROMs), assessed every three months, over the entire observation period: - Numeric rating scale for pain (NRS) - Pain medication intake (WHO pain scale) - Spinal Oncology Study group outcomes questionnaire 2.0 (SOSGOQ 2.0)

Secondary

MeasureTime frame
Complications of conservative/surgical management are assessed every 3 months as part of routine clinical tumor surveillance. This includes the occurrence of new/increasing pain, neurological deficits, pathological fractures. In the case of surgical treatment, occurrences such as wound healing problems, surgical site infections, hardware failure, revision surgeries, etc., are documented

Countries

Austria, Germany, Italy, Switzerland, United Kingdom, United States

Contacts

Public ContactEmily von Bronewski

Universitätsmedizin-Charité Berlin

emily-jasmina-christin.von-bronewski@charite.de+49 30 450 660 253

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026